Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mangoceuticals (MGRX) Gross Margin (2023 - 2025)

Mangoceuticals' Gross Margin history spans 3 years, with the latest figure at 60.42% for Q3 2025.

  • For Q3 2025, Gross Margin fell 157.0% year-over-year to 60.42%; the TTM value through Sep 2025 reached 60.61%, up 201.0%, while the annual FY2024 figure was 61.7%, 271.0% up from the prior year.
  • Gross Margin for Q3 2025 was 60.42% at Mangoceuticals, up from 53.51% in the prior quarter.
  • Across five years, Gross Margin topped out at 76.11% in Q4 2024 and bottomed at 42.77% in Q2 2024.
  • The 3-year median for Gross Margin is 58.98% (2023), against an average of 59.66%.
  • The largest YoY upside for Gross Margin was 1776bps in 2024 against a maximum downside of -1892bps in 2024.
  • A 3-year view of Gross Margin shows it stood at 58.35% in 2023, then soared by 30bps to 76.11% in 2024, then fell by -21bps to 60.42% in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Gross Margin are 60.42% (Q3 2025), 53.51% (Q2 2025), and 56.78% (Q1 2025).